Avalanche Biotechnologies to Present at Upcoming Investor Conferences
- Cowen and Company’s 36th Annual
Health Care Conferenceon Wednesday, March 9at 9:20 a.m. ETin Boston, and
- Alliance for Regenerative Medicine’s 4th Annual Cell and Gene Therapy Investor Day on
Tuesday, March 22at 4:50 p.m. ETin New York.
A recorded webcast of Mr. Cleveland’s presentation at the
Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients suffering from chronic or debilitating disease. Avalanche is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. With significant capabilities and expertise in vector optimization, process development and manufacturing, Avalanche seeks to discover and develop targets in ophthalmology and beyond.
Lauren Glaser, Head of Investor Relations (650) 656-9347 email@example.com